Human Dopaminergic Progenitor Cells Clinical Trials

3 actively recruiting trials across 1 location

No change since May 2026

Also known as: NouvNeu001

Pipeline

Phase 1: 1Phase 1/2: 2

Top Sponsors

iRegene Therapeutics Co., Ltd.3

Indications

Parkinson's Disease3
Parkinson Disease2
Early-onset Parkinson's Disease1

Other2 trials

The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

Phase 1/2

The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease

Phase 1

New York, New York1 trial

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

Cornell University Weill Medical College

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.